119 related articles for article (PubMed ID: 11337228)
21. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of distribution and drug resistance of pathogens of burn patients during 9 years].
Dou Y; Zhang Q
Zhonghua Shao Shang Za Zhi; 2018 Mar; 34(3):153-159. PubMed ID: 29609277
[No Abstract] [Full Text] [Related]
23. Changes in adherence of respiratory pathogens to HEp-2 cells induced by subinhibitory concentrations of sparfloxacin, ciprofloxacin, and trimethoprim.
Visser MR; Beumer H; Hoepelman AI; Rozenberg-Arska M; Verhoef J
Antimicrob Agents Chemother; 1993 Apr; 37(4):885-8. PubMed ID: 8388203
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of difloxacin against canine bacterial isolates.
van den Hoven R; Wagenaar JA; Walker RD
J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
Piddock LJ; Jin YF
J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
27. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
[TBL] [Abstract][Full Text] [Related]
28. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
[TBL] [Abstract][Full Text] [Related]
29. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
Gönüllü N; Aktaş Z; Salcioglu M; Bal C; Ang O
Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
[TBL] [Abstract][Full Text] [Related]
31. Antibacterial activity of cefepime in vitro.
Liu YC; Huang WK; Cheng DL
Chemotherapy; 1994; 40(6):384-90. PubMed ID: 7842821
[TBL] [Abstract][Full Text] [Related]
32. [In vitro activities of 23 antimicrobial agents against 4,993 gram-positive and gram-negative bacterial strains isolated from multicenter of Japan during 1994--in vitro susceptibility surveillance.Levofloxacin-Surveillance Group].
Yamaguchi K; Ohno A; Kashitani F; Iwata M; Shimizu Y; Sato S; Matsumoto I; Itoh M; Funato T; Tsujio Y; Nagasawa M; Tachibana M; Kanno H; Matsuda K; Okada J; Takaya H; Nakamura T; Igari J; Sugimoto K; Oguri T; Toyoshima S; Okada M; Nakai T; Kuwabara M; Nagasawa Z
Jpn J Antibiot; 1999 Feb; 52(2):75-92. PubMed ID: 10221176
[TBL] [Abstract][Full Text] [Related]
33. Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages.
Tino MJ; Wright JR
Am J Physiol; 1996 Apr; 270(4 Pt 1):L677-88. PubMed ID: 8928829
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
[No Abstract] [Full Text] [Related]
35. Effects on adhesiveness and hydrophobicity of sub-inhibitory concentrations of netilmicin.
Furneri PM; Garozzo A; Musumarra MP; Scuderi AC; Russo A; Bonfiglio G
Int J Antimicrob Agents; 2003 Aug; 22(2):164-7. PubMed ID: 12927958
[TBL] [Abstract][Full Text] [Related]
36. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
[TBL] [Abstract][Full Text] [Related]
38. Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States.
Gordon KA; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2003 Sep; 47(1):377-83. PubMed ID: 12967754
[TBL] [Abstract][Full Text] [Related]
39. Bacterial pathogens (non-Mycobacterium) from sputum culture and antimicrobial susceptibility.
Srifuengfung S; Sangsawang M; Komolpis P; Dhiraputra C; Chompanee B
Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):96-9. PubMed ID: 9740278
[TBL] [Abstract][Full Text] [Related]
40. Bacterial adhesion to respiratory mucosa and its modulation by antibiotics at sub-inhibitory concentrations.
Piatti G
Pharmacol Res; 1994 Dec; 30(4):289-99. PubMed ID: 7716103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
